Candid Therapeutics

Business news, market intelligence, and global industry analysis.

The Latest

VA Tech Wabag (NSE: WABAG) wins order from CMWSSB for 45 MLD Chennai TTRO plant

Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway

Representative image of enterprise cloud cybersecurity infrastructure illustrating how Accenture plc and Google Cloud are strengthening cloud security defenses against AI-driven cyber threats and multi-cloud security risks.

How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure

Four-decade-first: Lok Sabha votes down no-confidence motion against Speaker Om Birla

Candid Therapeutics launches first-in-class T-cell engager trials across five autoimmune diseases

Candid Therapeutics begins Phase 1 trials of BCMA and CD20 T-cell engagers across five autoimmune diseases; institutional interest builds around TCE approach.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

June 24, 2025